000057838 001__ 57838 000057838 005__ 20170503134900.0 000057838 0247_ $$2doi$$a10.1038/bjc.2014.38 000057838 0248_ $$2sideral$$a86486 000057838 037__ $$aART-2014-86486 000057838 041__ $$aeng 000057838 100__ $$aBujanda, L. 000057838 245__ $$aEffect of oral anticoagulants on the outcome of faecal immunochemical test 000057838 260__ $$c2014 000057838 5060_ $$aAccess copy available to the general public$$fUnrestricted 000057838 5203_ $$aBackground: We aimed to evaluate whether oral anticoagulants (OACs) alter faecal immunochemical test (FIT) performance in average-risk colorectal cancer (CRC) screening. Methods: Individuals aged 50–69 years were invited to receive one FIT sample (cutoff 75¿ng¿ml–1) between November 2008 and June 2011. Results: Faecal immunochemical test was positive in 9.3% (21 out of 224) of users of OAC and 6.2% (365 out of 5821) of non-users (P-trend=0.07). The positive predictive value (PPV) for advanced neoplasia (AN) in non-users was 50.4% vs 47.6% in users (odds ratio, 0.70; 95% CI, 0.3–1.8; P=0.5). The PPV for AN in OAC more antiplatelets (aspirin or clopidogrel) was 75% (odds ratio, 2; 95% CI, 0.4–10.8; P=0.4). Conclusions: Oral anticoagulant did not significantly modify the PPV for AN in this population-based colorectal screening program. The detection rate of advanced adenoma was higher in the combination OAC more antiplatelets. 000057838 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI08-90717 000057838 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-sa$$uhttp://creativecommons.org/licenses/by-nc-sa/3.0/es/ 000057838 590__ $$a4.836$$b2014 000057838 591__ $$aONCOLOGY$$b34 / 209 = 0.163$$c2014$$dQ1$$eT1 000057838 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000057838 700__ $$aSarasqueta, C. 000057838 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Á.$$uUniversidad de Zaragoza 000057838 700__ $$aQuintero, E. 000057838 700__ $$aCubiella, J. 000057838 700__ $$aHernandez, V. 000057838 700__ $$aMorillas, J.D. 000057838 700__ $$aPerez-Fernández, T. 000057838 700__ $$aSalas, D. 000057838 700__ $$aAndreu, M. 000057838 700__ $$aCarballo, F. 000057838 700__ $$aBessa, X. 000057838 700__ $$aPortillo, I. 000057838 700__ $$aJover, R. 000057838 700__ $$aBalaguer, F. 000057838 700__ $$aCosme, A. 000057838 700__ $$aCastells, A. 000057838 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDepartamento de Medicina, Psiquiatría y Dermatología$$cMedicina 000057838 773__ $$g110, 5 (2014), 1334-1337$$pBr. J. Cancer$$tBRITISH JOURNAL OF CANCER$$x0007-0920 000057838 8564_ $$s122640$$uhttps://zaguan.unizar.es/record/57838/files/texto_completo.pdf$$yVersión publicada 000057838 8564_ $$s102282$$uhttps://zaguan.unizar.es/record/57838/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000057838 909CO $$ooai:zaguan.unizar.es:57838$$particulos$$pdriver 000057838 951__ $$a2017-05-03-13:43:44 000057838 980__ $$aARTICLE